STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer
Journal of Gastroenterology · 2025
DOI: 10.1007/s00535-025-02291-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Xiao Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery, Cancer Center, Department of Hepatobiliary and Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospi…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Immune Checkpoint Inhibitors. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Medical Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited treatment options. Immunotherapy, though effective in various tumors, has limited efficacy in PDAC due to immune tolerance. Thus, identifying new targets to enhance immunotherapy response is crucial. METHODS: This study used bioinformatics analysis and public database data to identify STYK1 as a potential PDAC biomarker. We analyzed STYK1 expression in PDAC tissues, its link to patient prognosis and immune cell infiltration. In vitro experiments assessed the impact of STYK1 knockdown on PDAC cell proliferation, migration, and invasion. Immunohistochemical analysis was performed on 79 PDAC tissue samples to evaluate CD8+ T cell infiltration. In vivo studies examined the effects of STYK1 knockdown on tumor growth, T cell infiltration and activation, especially with anti-PD-L1 antibodies. We also investigated the molecular mechanisms of STYK1's regulation of T cell infiltration, focusing on its association with CCL20 and its role beyond the PD-1/PD-L1 pathway. RESULTS: Elevated STYK1 expression in PDAC tissue is associated with poor prognosis and reduced CD8+ T cell infiltration. STYK1 knockdown inhibits PDAC cell proliferation, migration, and invasion in vitro. In vivo, it decreases tumor growth and, when combined with anti-PD-L1 antibody treatment, significantly enhances T cell infiltration and activation without affecting PD-L1 expression. STYK1 regulates T cell infiltration via CCL20, independently of the PD-1/PD-L1 signaling pathway. CONCLUSIONS: STYK1 is a potential predictive biomarker for immunotherapy response in PDAC, as its regulation of T cell infiltration via CCL20, independent of the PD-1/PD-L1 pathway, may provide a strategy to potentially augment immunotherapy efficacy, pending mechanistic confirmation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Surgery, Cancer Center, Department of Hepatobiliary and Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou,…
- Urology and Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- Second Clinical Medical School, Zhejiang Chinese Medical University, Hangzhou, China.
- Shanghai Jiaotong University School of Medicine, Punan Branch of Renji Hospital, Shanghai, China.
- Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China. nanpeng_01@163.com.
ORCID-Profile: Xiao Wang
Förderung
- Medical Science and Technology Project of Zhejiang Province
Zitieren
APA
Wang, X., Zhang, Y., Li, A., Zhou, C., Xu, S., Gu, Z., Wang, W., Nan, P., & Tao, R. (2025). STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. Journal of Gastroenterology. https://doi.org/10.1007/s00535-025-02291-3
Vancouver
Wang X, Zhang Y, Li A, Zhou C, Xu S, Gu Z, et al. STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. Journal of Gastroenterology. 2025. doi:10.1007/s00535-025-02291-3
BibTeX
@article{Wang2025,
author = {Wang, Xiao and Zhang, Yueqin and Li, Anan and Zhou, Chuanzan and Xu, Sen and Gu, Zongting and Wang, Wei and Nan, Peng and Tao, Ran},
title = {STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer},
journal = {Journal of Gastroenterology},
year = {2025},
doi = {10.1007/s00535-025-02291-3}
}
EUVIMED